NSE 500 — The Filing Layer   CompaniesFilings

Granules India Ltd.

GRANULESHealthcare filings

We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.

Earnings calls

3 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 3 documents here); elsewhere sentences render unattributed.

KindDatePeriodServedAttribution rate
TRANSCRIPT202105122021-03-31yes
TRANSCRIPT202105132021-03-31yes
TRANSCRIPT202311162024-03-31yes
TRANSCRIPT202405212024-03-31yes
TRANSCRIPT202408022024-06-30yes
TRANSCRIPT202411132024-09-30yes
TRANSCRIPT202508192025-06-30yes
TRANSCRIPT202511192025-09-30yes
TRANSCRIPT202601282025-12-31yes
TRANSCRIPT202605052026-03-31yes
TRANSCRIPT202607272026-06-30yes

GRANULES

files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.

Identity

Statement divisiongeneral
Scope servedconsolidated
Panels on this page4

Market

No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.

Last close853.00
52-week range514.6 – 909.3
Return 1M0.83%
Return 3M11.62%
Return 1Y60.7%
Return 3Y155.58%
Return 5Y165.07%
Market capitalisationnot shown — we could not confirm it
Shares outstandingnot shown — we could not confirm it
P/Enot shown — we could not confirm it
P/Bnot shown — we could not confirm it
EV/EBITDAnot shown — we could not confirm it

Latest quarter filed — period ending 2026-06-30

In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.

Revenue from operations1,477.00
Other income2.00
Total income1,479.00
Cost of materials consumed496.00
Purchases of stock-in-trade0.00
Changes in inventories12.00
Employee benefit expense255.00
Finance costs21.00

Ownership — 2026-06-30, and the change from 2026-03-31

HolderPer centChange
promoter and promoter group0.380.00
institutions foreign0.170.02
institutions domestic0.16-0.01
mutual funds0.030.01
public0.620.00

Documents on file

ClassMost recentOn file
TRANSCRIPT2026-06-3011

Financial statements

Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.

Quarterly results, as filed

Line2022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-302024-09-302024-12-312025-03-312025-06-302025-09-302025-12-312026-03-312026-06-30
Revenue from operations1,151.001,146.001,196.00986.001,189.001,156.001,176.001,180.00967.001,138.001,197.001,210.001,297.001,388.001,471.001,477.00
Other income5.001.003.000.002.001.002.002.003.006.002.0016.00-1.00-4.009.002.00
Total income1,156.001,147.001,199.00986.001,191.001,156.001,178.001,182.00970.001,143.001,199.001,226.001,296.001,384.001,479.001,479.00
Cost of materials consumed618.00594.00604.00589.00520.00553.00547.00483.00362.00445.00435.00429.00498.00529.00644.00496.00
Purchases of stock-in-trade0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Changes in inventories-40.00-2.0019.00-109.0055.00-56.00-77.001.005.00-9.004.00-3.00-53.00-28.00-140.0012.00
Employee benefit expense118.00119.00127.00140.00149.00157.00152.00164.00159.00168.00169.00203.00219.00226.00240.00255.00
Finance costs13.0017.0019.0022.0026.0029.0029.0027.0026.0027.0024.0024.0029.0029.0033.0021.00
Depreciation and amortisation44.0048.0049.0049.0053.0052.0053.0053.0053.0057.0063.0069.0072.0074.0082.0080.00
Other expenses212.00204.00217.00229.00253.00251.00299.00273.00237.00304.00338.00336.00355.00352.00374.00375.00
Total expenses965.00980.001,035.00920.001,055.00986.001,002.001,000.00841.00991.001,033.001,056.001,120.001,182.001,233.001,239.00
Profit before exceptional items and tax190.00167.00164.0065.00136.00170.00176.00181.00128.00153.00167.00170.00176.00202.00246.00240.00
Exceptional items0.000.000.000.000.000.000.000.000.000.0031.00-26.000.000.0016.000.00
Profit before tax190.00167.00164.0065.00136.00170.00176.00181.00128.00153.00198.00145.00176.00202.00262.00240.00
Current tax38.0051.0047.0026.0036.0054.0049.0053.0031.0037.0062.0038.0051.0073.0034.0065.00
Deferred tax8.00-8.00-3.00-8.00-2.00-10.00-3.00-6.00-0.00-2.00-16.00-6.00-6.00-21.0027.00-4.00
Tax expense45.0043.0044.0018.0034.0044.0046.0047.0031.0035.0046.0032.0045.0052.0061.0060.00
Profit for the period145.00124.00120.0048.00102.00126.00130.00135.0097.00118.00152.00113.00131.00150.00202.00180.00
Profit attributable to owners145.00124.00120.00——126.00139.00135.0097.00118.00152.00110.00131.00150.00—180.00
Profit attributable to non-controlling interests——0.00——0.000.000.000.000.000.000.000.000.00—0.00
Other comprehensive income37.00-9.002.000.0016.00-5.009.002.004.0010.0011.0019.0039.0019.0066.0030.00
Total comprehensive income182.00115.00121.0048.00118.00121.00139.00137.00101.00128.00163.00132.00170.00169.00268.00210.00
Earnings per share, basic5.855.114.941.984.225.185.355.564.014.856.274.645.386.198.237.26
Earnings per share, diluted5.825.104.931.984.225.185.355.554.014.856.274.645.386.198.237.12

Annual results, as filed

Line2019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Revenue from operations2,279.002,599.003,238.003,765.004,512.004,506.004,482.005,366.00
Other income27.0037.0027.0018.0014.004.0013.0020.00
Total income2,306.002,635.003,264.003,783.004,526.004,511.004,495.005,386.00
Cost of materials consumed1,339.001,315.001,590.002,036.002,353.002,208.001,725.002,100.00
Purchases of stock-in-trade0.000.000.000.000.000.000.000.00
Changes in inventories-83.00-34.00-199.00-153.00-45.00-187.001.00-224.00
Employee benefit expense210.00259.00408.00401.00472.00598.00660.00888.00
Finance costs28.0027.0026.0023.0056.00106.00103.00114.00
Depreciation and amortisation105.00137.00151.00159.00184.00207.00226.00296.00
Other expenses430.00533.00583.00758.00819.001,031.001,151.001,416.00
Total expenses2,029.002,237.002,560.003,225.003,839.003,964.003,865.004,591.00
Profit before exceptional items and tax277.00398.00704.00558.00687.00547.00629.00795.00
Exceptional items0.0028.000.000.000.000.0031.00-10.00
Profit before tax277.00426.00704.00558.00687.00547.00660.00785.00
Current tax82.00126.00195.00138.00177.00165.00183.00196.00
Deferred tax7.00-10.00-40.007.00-7.00-23.00-24.00-6.00
Tax expense89.00116.00155.00145.00171.00142.00159.00190.00
Profit for the period236.00335.00549.00413.00517.00405.00502.00595.00
Profit attributable to owners0.000.00—413.00517.00426.00502.00—
Profit attributable to non-controlling interests0.000.00—0.000.000.000.00—
Other comprehensive income13.002.00-26.0040.0057.0020.0027.00143.00
Total comprehensive income249.00338.00523.00453.00574.00426.00529.00738.00
Earnings per share, basic9.3013.1922.0516.6621.0516.7320.6924.47
Earnings per share, diluted9.2813.1521.9516.6021.0016.7220.6824.46

Balance sheet, as filed

Line2022-09-302023-03-312023-09-302024-03-312024-09-302025-03-312025-09-302026-03-31
Total assets4,858.004,905.005,265.005,521.005,433.006,253.006,944.007,720.00
Non-current assets2,130.002,330.002,473.002,616.002,827.003,137.003,857.003,952.00
Current assets2,729.002,574.002,792.002,905.002,605.003,115.003,087.003,768.00
Property, plant and equipment1,431.001,631.001,787.001,856.001,893.002,217.002,612.003,051.00
Capital work-in-progress297.00228.00219.00260.00411.00437.00702.00406.00
Goodwill0.000.000.000.000.000.0012.0012.00
Other intangible assets266.00280.00260.00240.00224.00209.00189.00187.00
Inventories1,163.001,149.001,280.001,301.001,395.001,343.001,488.001,673.00
Trade receivables846.00949.001,016.00986.00727.00942.00761.00909.00
Cash and cash equivalents395.00292.00295.00381.00209.00466.00609.00880.00
Total equity and liabilities4,858.004,905.005,265.005,521.005,433.006,253.006,944.007,720.00
Equity2,598.002,835.002,967.003,226.003,427.003,716.003,983.005,085.00
Equity share capital25.0024.0024.0024.0024.0024.0024.0025.00
Other equity2,573.002,811.002,943.003,201.003,403.003,691.003,959.005,060.00
Total liabilities2,260.002,070.002,297.002,295.002,005.002,537.002,961.002,635.00
Non-current liabilities242.00256.00228.00213.00314.00534.00544.00543.00
Current liabilities2,017.001,814.002,069.002,082.001,692.002,003.002,417.002,092.00
Borrowings, non-current177.00149.0098.0069.00157.00312.00318.00297.00
Borrowings, current883.00910.001,187.001,154.00853.00974.001,320.001,041.00
Trade payables707.00782.00729.00750.00635.00726.00755.00673.00

Cash flow, as filed

Line2022-09-302023-03-312023-09-302024-03-312024-09-302025-03-312025-09-302026-03-31
Net cash from operating activities398.00739.0036.00439.00417.00867.00474.00793.00
Net cash from investing activities-112.00-191.00-170.00-360.00-279.00-691.00-499.00-773.00
Net cash from financing activities-76.00-440.00136.008.00-311.00-93.00159.00379.00
Purchase of property, plant and equipment176.00411.00177.00381.00277.00572.00325.00558.00
Net increase in cash210.00107.004.0090.00-172.0085.00142.00412.00
con:CFO.BEFORE_TAX482.00915.00112.00630.00478.001,010.00563.001,033.00
con:INTEREST_RECEIVED.OPERATING0.000.000.000.000.000.000.000.00
con:INTEREST_PAID.OPERATING0.000.000.000.000.000.000.000.00
con:DIVIDENDS_RECEIVED.OPERATING0.000.000.000.000.000.000.000.00
con:TAX_PAID.OPERATING84.00176.0076.00190.0061.00144.0089.00240.00
con:CF_OTHER.OPERATING0.000.000.000.000.000.000.000.00
con:INVESTMENTS_PURCHASED0.000.000.000.000.000.00198.000.00
con:INVESTMENTS_SOLD0.000.000.000.000.000.000.0032.00
con:PPE_DISPOSALS0.000.001.002.000.000.000.004.00
con:CF_INVESTING.SUBSIDIARIES_SOLD0.000.000.000.000.000.000.000.00
con:CF_INVESTING.SUBSIDIARIES_ACQUIRED0.000.000.000.000.000.000.00198.00
con:CF_INVESTING.JV_SOLD0.000.000.000.000.000.000.000.00
con:CF_INVESTING.JV_ACQUIRED0.000.000.000.000.000.000.000.00

Who owns it

The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.

Holder2023-03-312023-06-302023-09-302023-12-312024-03-312024-06-302024-09-302024-12-312025-03-312025-09-302025-12-312026-02-232026-03-312026-06-30
Promoter and promoter group42.0242.0241.9641.9641.9638.8738.8738.8538.840.390.390.380.380.38
Domestic institutions5.036.687.0610.1610.7014.1214.8719.5722.450.180.170.190.170.16
Mutual funds—————————0.070.050.040.030.03
Insurance companies1.271.812.923.093.594.696.128.4410.130.110.110.100.100.09
Foreign institutions23.9021.3521.4818.7819.5720.3919.4915.8715.150.140.140.140.150.17
Public57.9857.9858.0458.0458.0461.1361.1361.1561.160.610.610.620.620.62
Non-institutional29.0529.9529.5029.1027.7626.6226.7825.7123.570.290.300.300.300.28
Shares outstanding242042756242042756242368716242368716242368716242368716242368716242493716242543716242668716242668716247796921247796921247796921

Related parties

Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.

CounterpartyRelationshipTypeAmount in the periodTransactions
Granules Consumer Health IncStep down subsidiaryAny other transaction, Loan, Purchase of goods or se3,730,560,000.0013
Granules Pharmaceuticals IncSubsidiaryAny other transaction, Investment, Purchase of goods3,294,180,000.009
Granules Life Sciences Pvt LtdSubsidiaryAny other transaction, Investment, Purchase of goods1,686,470,000.009
Granules USA IncSubsidiaryAny other transaction, Investment, Purchase of goods912,030,000.0013
Product Armor Packaging Pvt LtdEnterprises over which key managemAny other transaction, Purchase of goods or services213,450,000.004
Granules CZRO Pvt LtdSubsidiaryAny other transaction, Investment202,710,000.004
Dr. Krishna Prasad ChigurupatiKey Management PersonnelAny other transaction101,920,000.001
Dr. K.V.S. Ram RaoKey Management PersonnelAny other transaction41,810,000.001
Granules Europe LtdSubsidiaryAny other transaction, Investment, Loan38,940,000.004
Key Management PersonnelKey Management PersonnelAny other transaction28,030,000.001
Granules TrustEnterprises over which key managemAny other transaction25,000,000.001
Mrs. Uma Devi ChigurupatiKey Management PersonnelAny other transaction10,190,000.001
Mr. Harsha ChigurupatiKey Management PersonnelAny other transaction10,190,000.001
Mrs. Priyanka ChigurupatiKey Management PersonnelAny other transaction10,190,000.001
Non Executive DirectorsNon Executive DirectorAny other transaction8,470,000.001

What management said

Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.

DateQuarterWho spoke
2023-11-16FYFY24DIRECTOR, GRANULES INDIA LIMITED.Read the call
2021-05-13FYFY21OperatorRead the call
2021-05-12FYFY21GRANULES PHARMACEUTICALS INC.Read the call

What they said about it, quarter by quarter

TopicFYFY21FYFY24
CapexThe contracts that we are entering in right now, are those kind of a fixed price contract in terms of we'll buy at certain price because they will als…CAPEX spend during the quarter was 1029 million.
Capital allocation—So, do we have any dividend policy in the company?
CostsSudarshan Padmanabhan Sundaram Asset Management Company Ltd. - Research Analyst My question is to understand a little bit more about the raw material …Price erosions were offset by the reduction in rates of key raw materials.
Debt and cashOur operational cash flow for the year at INR 432 crores versus INR 476 crores in the previous year, mainly on account of increase in working capital …Granules India Limited November 09, 2023 Our net debt was 9895 million as compared to 7671 million at the beginning of the year.
Demand—So, what exactly is driving this, are there some specific launches or it’s the general pricing and demand environment that we are seeing in that marke…
GuidanceThey're moving to a new site, and we expect this to start in the next 2 or 3 quarters.Significant progress has happened on these dosage forms, and we expect to file new dosage forms in the near future.
MarginAnil Sarin Centrum Wealth Management Limited - Executive Director & CIO-Centrum PMS Congratulations on an actually elevated margin despite the PAP pro…EBITDA for the quarter was, Rs.2130 million, 17.9% of sales as compared to 2429 million, 21.1% of sales in Q2 FY23, a decrease of 12% in value terms o…
PricingSo we can partially pass on the price increases.And there are some changes that I mentioned earlier in my discussion that have happened in the market, which have enabled us to pick up more market sh…
Revenue growthSo what we are saying is 20% revenue growth.The second quarter revenue were Rs.11,895 million as compared to 11,507 million in Q2 FY23. A growth of 3% in value terms.

What they said they would do

Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.

DateQuarterWhoWhat they said
2021-05-13FYFY21OperatorKrishna Prasad Chigurupati Granules India Limited - Chairman & MD For the current fiscal, we expect that the growth – the EBITDA also will be around 20% and growth also over the base of '21 will be 20%. * (please see note above) Tushar Manudhane Motilal Oswal Securities Limited, Research Division - Research Analyst And the scope of passing on the raw material price hike to the customers, how do we see that changing?
2021-05-13FYFY21OperatorSo our guidance of 30% EBITDA margin, does that assume significant deflation in PAP prices in, let's say, quarter 3 or quarter 4?
2021-05-13FYFY21OperatorFY '22, we expect to spend INR 400 crores in '22.